Episode 46: The impact of COVID-19 on the healthcare industry and policy decisions
As countries and organizations start to reopen, the question top-of-mind for many is when will a vaccine, or other treatment, be available? Many hold out hope that a vaccine will be the magic bullet — it’s not that simple. Our life science’s experts Gustav Ando and Milena Izmirlieva spend todays’ episode discussing the challenges and opportunities for developing a vaccine as well as the alternative therapies that are being tested in tandem to alleviate many of the symptoms of COVID-19. How has the industry risen to the challenge and what does this mean for future R&D? Gustav Ando, Vice President, Industry Services & Life Sciences, IHS Markit https://ihsmarkit.com/experts/ando-gustav.html Milena Izmirlieva, Director, Life Sciences, IHS Markit https://ihsmarkit.com/experts/izmirlieva-milena.html